These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 24224933)

  • 21. Computational prediction of metabolism: sites, products, SAR, P450 enzyme dynamics, and mechanisms.
    Kirchmair J; Williamson MJ; Tyzack JD; Tan L; Bond PJ; Bender A; Glen RC
    J Chem Inf Model; 2012 Mar; 52(3):617-48. PubMed ID: 22339582
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Computational prediction of binding affinity for CYP1A2-ligand complexes using empirical free energy calculations.
    Vasanthanathan P; Olsen L; Jørgensen FS; Vermeulen NP; Oostenbrink C
    Drug Metab Dispos; 2010 Aug; 38(8):1347-54. PubMed ID: 20413725
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Compound lipophilicity for substrate binding to human P450s in drug metabolism.
    Lewis DF; Jacobs MN; Dickins M
    Drug Discov Today; 2004 Jun; 9(12):530-7. PubMed ID: 15183161
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metabolism site prediction based on xenobiotic structural formulas and PASS prediction algorithm.
    Rudik AV; Dmitriev AV; Lagunin AA; Filimonov DA; Poroikov VV
    J Chem Inf Model; 2014 Feb; 54(2):498-507. PubMed ID: 24417355
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytochrome P450 networks in chemical space.
    Lee S; Kim D
    Arch Pharm Res; 2010 Sep; 33(9):1361-74. PubMed ID: 20945135
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ligand-based models for the isoform specificity of cytochrome P450 3A4, 2D6, and 2C9 substrates.
    Terfloth L; Bienfait B; Gasteiger J
    J Chem Inf Model; 2007; 47(4):1688-701. PubMed ID: 17608404
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Scaling drug biotransformation data from cDNA-expressed cytochrome P-450 to human liver: a comparison of relative activity factors and human liver abundance in studies of mirtazapine metabolism.
    Störmer E; von Moltke LL; Greenblatt DJ
    J Pharmacol Exp Ther; 2000 Nov; 295(2):793-801. PubMed ID: 11046120
    [TBL] [Abstract][Full Text] [Related]  

  • 28. DeepP450: Predicting Human P450 Activities of Small Molecules by Integrating Pretrained Protein Language Model and Molecular Representation.
    Chang J; Fan X; Tian B
    J Chem Inf Model; 2024 Apr; 64(8):3149-3160. PubMed ID: 38587937
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comprehensive characterization of cytochrome P450 isozyme selectivity across chemical libraries.
    Veith H; Southall N; Huang R; James T; Fayne D; Artemenko N; Shen M; Inglese J; Austin CP; Lloyd DG; Auld DS
    Nat Biotechnol; 2009 Nov; 27(11):1050-5. PubMed ID: 19855396
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel Electrotopological Atomic Descriptors for the Prediction of Xenobiotic Cytochrome P450 Reactions.
    Kaitoh K; Kotera M; Funatsu K
    Mol Inform; 2019 Oct; 38(10):e1900010. PubMed ID: 31187601
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of protein flexibility and active site water molecules on the prediction of sites of metabolism for cytochrome P450 2C19 substrates.
    Li J; Cai J; Su H; Du H; Zhang J; Ding S; Liu G; Tang Y; Li W
    Mol Biosyst; 2016 Mar; 12(3):868-78. PubMed ID: 26761525
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chemical proteomic tool for ligand mapping of CYP antitargets: an NMR-compatible 3D QSAR descriptor in the Heme-Based Coordinate System.
    Yao H; Costache AD; Sem DS
    J Chem Inf Comput Sci; 2004; 44(4):1456-65. PubMed ID: 15272854
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Complementarity between in silico and biophysical screening approaches in fragment-based lead discovery against the A(2A) adenosine receptor.
    Chen D; Ranganathan A; IJzerman AP; Siegal G; Carlsson J
    J Chem Inf Model; 2013 Oct; 53(10):2701-14. PubMed ID: 23971943
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cytochromes P450: a structure-based summary of biotransformations using representative substrates.
    Brown CM; Reisfeld B; Mayeno AN
    Drug Metab Rev; 2008; 40(1):1-100. PubMed ID: 18259985
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Virtual screening for cytochromes p450: successes of machine learning filters.
    Burton J; Ijjaali I; Petitet F; Michel A; Vercauteren DP
    Comb Chem High Throughput Screen; 2009 May; 12(4):369-82. PubMed ID: 19442071
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular modeling information transfer with VRML: from small molecules to large systems in bioscience.
    Moeckel G; Keil M; Exner T; Brickmann J
    Pac Symp Biocomput; 1998; ():327-38. PubMed ID: 9697193
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improved Prediction of CYP-Mediated Metabolism with Chemical Fingerprints.
    Zaretzki J; Boehm KM; Swamidass SJ
    J Chem Inf Model; 2015 May; 55(5):972-82. PubMed ID: 25871613
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human CYPs involved in drug metabolism: structures, substrates and binding affinities.
    Lewis DF; Ito Y
    Expert Opin Drug Metab Toxicol; 2010 Jun; 6(6):661-74. PubMed ID: 20402561
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Substrate selectivity of drug-metabolizing cytochrome P450s predicted from crystal structures and in silico modeling.
    Dong D; Wu B; Chow D; Hu M
    Drug Metab Rev; 2012 May; 44(2):192-208. PubMed ID: 22251142
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterizing binding of small molecules. II. Evaluating the potency of small molecules to combat resistance based on docking structures.
    Ding B; Li N; Wang W
    J Chem Inf Model; 2013 May; 53(5):1213-22. PubMed ID: 23570305
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.